The stock of Stemline Therapeutics Inc (NASDAQ:STML) hit a new 52-week high and has $20.41 target or 79.00% above today’s $11.40 share price. The 5 months bullish chart indicates low risk for the $214.81 million company. The 1-year high was reported on Oct, 7 by Barchart.com. If the $20.41 price target is reached, the company will be worth $169.70M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 264,293 shares traded hands or 55.95% up from the average. Stemline Therapeutics Inc (NASDAQ:STML) has risen 92.43% since March 4, 2016 and is uptrending. It has outperformed by 84.39% the S&P500.
Analysts await Stemline Therapeutics Inc (NASDAQ:STML) to report earnings on November, 4. They expect $-0.55 earnings per share, down 3.77% or $0.02 from last year’s $-0.53 per share. After $-0.52 actual earnings per share reported by Stemline Therapeutics Inc for the previous quarter, Wall Street now forecasts 5.77% negative EPS growth.
According to Zacks Investment Research, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.12, from 0.96 in 2016Q1. The ratio improved, as 9 funds sold all Stemline Therapeutics Inc shares owned while 15 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 9.63 million shares or 1.71% less from 9.80 million shares in 2016Q1.
Perceptive Ltd Limited Liability Company holds 78,603 shares or 0.04% of its portfolio. Schwab Charles Invest Mngmt holds 26,000 shares or 0% of its portfolio. Paradigm Asset Management Co Limited Liability Co accumulated 0% or 20,800 shares. The North Carolina-based State Bank Of America Corp De has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Blackrock Fund holds 0% or 438,016 shares in its portfolio. Ladenburg Thalmann Services holds 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML) for 1,394 shares. Baker Bros Advisors Ltd Partnership has 0.02% invested in the company for 333,497 shares. Dimensional Fund Advsrs L P, a Texas-based fund reported 34,337 shares. Fmr Ltd Co last reported 1.86 million shares in the company. Wells Fargo And Mn holds 0% or 7,834 shares in its portfolio. Timessquare Capital Management Lc reported 950,005 shares or 0.04% of all its holdings. Bnp Paribas Arbitrage Sa accumulated 0% or 652 shares. Vhcp Mngmt Limited Liability Co accumulated 0.95% or 135,420 shares. Stoneridge Prtn Ltd, a Pennsylvania-based fund reported 33,890 shares. Blackrock Lc holds 7,303 shares or 0% of its portfolio.
Another recent and important Stemline Therapeutics Inc (NASDAQ:STML) news was published by Marketwatch.com which published an article titled: “- Edgar Online – (EDG = 10Q, 10K)” on August 22, 2012.
STML Company Profile
Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.